Phase 2 N=40 Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Osteosarcoma
Primary: Radiographic Response — 21; 5; 5; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,409 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of…
N/A N=299 SuperNOVA Clinical Stenting Trial
Atherosclerosis of Native Arteries of the Extremities, Unspecified
Primary: Primary Safety Endpoint and Components — 85.8; 14.2; 0.0; 0.4 percentage of participants
Phase 2 N=197 A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
Primary: Progression-Free Survival (PFS) — 5.22; 4.21 Months
Phase 4 N=2,262 EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
Coronary Artery Disease
Primary: Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects — 4.3; 4.8; 16.9…
Phase 4 N=75 Unicirc vs Open Surgical Circumcision
Circumcision, Male
Primary: Time Elapsed From First Clamp (Surgical) or Start of Insertion of Bell (Unicirc) to Beginning of Wound Dressing — 12; 25 Minutes
N/A N=35 Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Complete Pathologic Response — 8; 21; 1 participants
Phase 2 N=42 Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Ovarian Cancer · Primary PERITONEUM · Fallopian Tube Cancer
Primary: Overall Objective Response — 10; 13; 11; 4 participants
Phase 2 N=12 Determination of Absorption and Elimination of Lamotrigine-XR
Epilepsy · Seizures · Bipolar Disorder
Primary: Area Under the Curve (AUC) for Oral Bioavailability of Lamotrigine (LTG — 142.8; 132.3 µg*h/mL
Phase 4 N=6,661 A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs) — 2058; 67 Participants
Phase 2 N=25 Reversing Type 1 Diabetes After it is Established
Diabetes Mellitus, Type 1
Primary: Change in Metabolic Function Baseline to 12 Months. — 0.74; 0.43 nmol/L/min — p=0.017
Phase 2 N=81 Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Primary: Overall Objective Response of OSI-774 — 1; 18; 31; 30 participants
Phase 4 N=88 Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
Chronic Obstructive Pulmonary Disease · COPD
Primary: Forced Expiratory Volume in One Second (FEV1) at 1 h Post-inhalation — 1.676; 1.595 Liters — p=0.0017
N/A N=1,143 Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
Pneumococcal Vaccine · Streptococcus Pneumoniae
Primary: Number of Participants With Adverse Reactions — 126 participants
Phase 2 N=41 Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Progression Free Survival (PFS) Rate as Measured at Week 8 — 20; 20 percentage of participants